The modified prolactin-releasing peptide NN501 reduced body weight comparably to GLP-1 drugs but primarily through sustained energy expenditure and fatty-acid oxidation rather than appetite suppression, with slower weight regain after discontinuation.
Different mechanismNN501 loses weight through energy burning, not appetite suppression — fundamentally different from GLP-1 drugs
What the researchers found
NN501 reduced body weight comparably to GLP-1 RAs but with only modest food intake reduction, primarily through increased energy expenditure and fatty-acid oxidation, with more gradual weight regain and no compensatory hyperphagia after discontinuation.
Why it matters
Weight regain is the biggest limitation of current GLP-1 drugs. A peptide that maintains weight loss through energy burning rather than appetite suppression could provide more durable results.
How the study worked
Preclinical study of NN501 (GPR10/NPFFR2 agonist) in mice, comparing weight loss mechanisms to GLP-1 receptor agonism using body weight, food intake, energy expenditure, fatty-acid oxidation, and post-treatment weight regain assessments.
What this study cannot tell us
Mouse model only. Human GPR10/NPFFR2 biology may differ. Long-term effects and safety profile unknown. Not tested in combination with GLP-1 drugs.
How to read the evidence
Preclinical study with mechanistic characterization. Novel peptide target with promising but early-stage evidence.
When this study was published
Published in 2025.
The bigger picture
This identifies a new peptide receptor pathway for obesity that could either replace or synergize with GLP-1 drugs, potentially solving the weight regain problem.
Questions still open
- Would combining NN501 with GLP-1 drugs produce additive weight loss?
- Does NN501 maintain metabolic improvements during weight regain?
- Is the human GPR10/NPFFR2 system a viable drug target?
Common questions
How is this different from Ozempic?
Could this solve the weight regain problem?
Read the original research
Analog of prolactin-releasing peptide reduces body weight primarily through sustained fatty acid oxidation rather than hypophagia.
Cell metabolism, 38(1), 100-114.e6
Citation
Feetham, Claire H; Groom, Sam; John, Linu M; Christoffersen, Berit Ostergaard; Collabolletta, Valeria; Lyons, David; Adamson, Antony; Lundh, Sofia; Gerstenberg, Marina Kjærgaard; Tang-Christensen, Mads; Conde-Frieboes, Kilian W; Secher, Anna; Kruse Hansen, Ann Maria; Luckman, Simon M. (2026). Analog of prolactin-releasing peptide reduces body weight primarily through sustained fatty acid oxidation rather than hypophagia.. Cell metabolism, 38(1), 100-114.e6. https://doi.org/10.1016/j.cmet.2025.10.021